David Beyer
Partner @ Amplify Partners
San Francisco, United States
David Beyer is a seed investor at Amplify Partners in San Francisco focused on Software and Artificial Intelligence. David is a Partner of Amplify Partners and co-founder of Chartio.com.Before joining Amplify Partners, David spent time as both a venture-backed entrepreneur and an early-stage investor. He began his career in technology as the co-founder and CEO of Chartio.com, a pioneering provider of cloud-based data visualization and analytics. He wassubsequently part of the founding team at Patients Know Best, one of the world’s leading cloud-based personal health record companies. David has been a prolific investor and advisor to entrepreneurs. He has personally invested in more than 50 early-stage companies, including Zymergen, Skycatch, Caribou Biosciences, Rigetti Computing, Casetext, Ginkgo Bioworks, Function of Beauty, Cruise Automation, and Bugcrowd. In addition, he currently serves on the advisory council of Bayes Impact, a nonprofit organization that deploys data science to solve important social challenges.He attended Brown University.
- Total investments:
- 38
- Last investment:
- Lead investor:
- 8%
Last updated:
For AI agents: llms.txt
Industries David Beyer invests in
Stages David Beyer invests in
Countries David Beyer invests in
Round sizes
Round size
- Seed
- $1.2M–$4M
- Angel
- $500k–$2.2M
- Series A
- $2.7M–$23M
Investment Focus
Industry
- Software 11 (29%)
- Artificial Intelligence 9 (24%)
- Machine Learning 6 (16%)
- Enterprise Software 6 (16%)
- Mobile 5 (13%)
Stage
- Seed 22 (58%)
- Series A 5 (13%)
- Angel 3 (8%)
- Pre-Seed 2 (5%)
- Series B 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Allium
|
Allium provides blockchain data infrastructure for institutions and crypto-focused organizations. It collects, verifies, and standardizes data from more than 150 blockchains and thousands of protocols, making on-chain activity easier to analyze and use in operational workflows. The company delivers historical and real-time data through APIs, datastreams, data shares, dashboards, and query tools. Its datasets support applications such as transaction reconciliation, analytics, compliance, payments, and digital asset research. Allium also offers tools for querying, visualizing, and accessing blockchain data to help organizations build applications and monitor activity across multiple blockchain networks. | $40M / Series B / Jun 23, 2026 | |
Luma AI
|
Luma AI develops tools that let users generate photorealistic images and videos from text, image, or video prompts via its Dream Machine platform. Its models learn from multimodal data, including video, audio, and language to build “world models” that can reason about motion, context, and physics. It provides access through a web app, iOS app, andAPI, enabling creative professionals to scale visuals for storytelling, advertising, animation, gaming, and more. For enterprises, Luma offers a secure full-stack solution with data ownership, legal clarity, and customizable AI models. | $900M / Series C / Nov 19, 2025 | |
Bexorg
|
Bexorg is a techbio company that supports central nervous system drug discovery and development. The company uses its proprietary wet-lab platform, BrainEx, to generate human brain data. It trains predictive models and creates an AI engine to facilitate drug discovery research. | $23M / Series A / Oct 15, 2025 | |
|
Luma AI
|
Luma AI develops tools that let users generate photorealistic images and videos from text, image, or video prompts via its Dream Machine platform. Its models learn from multimodal data, including video, audio, and language to build “world models” that can reason about motion, context, and physics. It provides access through a web app, iOS app, andAPI, enabling creative professionals to scale visuals for storytelling, advertising, animation, gaming, and more. For enterprises, Luma offers a secure full-stack solution with data ownership, legal clarity, and customizable AI models. | $20M / Series A / Mar 20, 2023 | |
Cubist
|
Cubist brings modern software engineering practices and first-class security to web3 builders. Cubist’s toolkit makes it safe and easy to build, test and deploy multi-chain and cross-chain dapps in automated pipelines that handle keys and sequencing. | $7M / Seed / Mar 09, 2023 | |
Continual
|
Continual is the easiest way to maintain predictions – from customer churn to inventory forecasts – in your data warehouse. It's built for modern data teams that want to leverage machine learning to drive revenue, streamline operations, and power innovative products and services without complex engineering. | $14.5M / Series A / Jun 08, 2022 | |
|
Continual
|
Continual is the easiest way to maintain predictions – from customer churn to inventory forecasts – in your data warehouse. It's built for modern data teams that want to leverage machine learning to drive revenue, streamline operations, and power innovative products and services without complex engineering. | $4M / Seed / Dec 16, 2021 | |
VeriSIM Life
|
VeriSIM Life is a computational bioplatform that predicts the clinical outcomes of new drugs before clinical trials. VeriSIM offers a range of translational-based solutions, customized for the pre-clinical and clinical programs. These offerings are all centered around their proven and validated BIOiSIMTM platform for small molecules, largemolecules, and viruses. | $1.2M / Pre-Seed / Jan 01, 2018 | |
Astranis
|
Astranis develops small communications satellites designed for geostationary and other high Earth orbits. The company manufactures software-defined satellites used for broadband connectivity, government communications, navigation resilience, and space-based infrastructure applications. Its MicroGEO platform is built to provide dedicated satellitecapacity for telecommunications providers, enterprises, and public sector organizations serving remote or underserved regions. Astranis also develops satellite systems with onboard propulsion, radiation-hardened electronics, and configurable bandwidth management technologies for mission flexibility. The company operates across spacecraft design, satellite manufacturing, launch coordination, and in-orbit operations through integrated engineering and testing capabilities. Its satellite network solutions support internet connectivity, defense communications, and resilient positioning and navigation services for commercial and government customers. | Pre-Seed / Jan 09, 2016 | |
Ginkgo Bioworks
|
Ginkgo Bioworks is a biotechnology firm. It is a developer of biological engineering products and custom microbes across multiple markets. It designs, engineer, develops, tests, and licenses organisms. It discovers molecules in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. It also provides probiotic bacteria toprotect the body from dangerous infections, and it generates libraries of molecules. It serves cultured ingredients, carbon mitigation, probiotics, and natural product discovery markets. | $9M / Series A / Mar 18, 2015 | |
| See all 38 investments → | |||
Co-Investors
About Amplify Partners
Amplify Partners invests in technical founders solving technical problems for the enterprise. They invest in early-stage companies pioneering novel applications in machine intelligence and computer science.
Amplify Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Daniel Tunkelang
Venture Amplifier
|
|||
|
David Beyer
Partner
|
|||
Elliot Hershberg
Partner
|
|||
Grace Ge
Partner
|
|||
Justin Gage
Developer Marketing
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does David Beyer invest in?
David Beyer invests primarily in Software, Artificial Intelligence and Machine Learning startups, most often at Seed and Series A stage. Most of the 38 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is David Beyer's check size?
David Beyer typically joins rounds of $1.2M–$4M at Seed, $500k–$2.2M at Angel and $2.7M–$23M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds David Beyer participates in.
When did David Beyer last invest?
The most recent investment recorded for David Beyer closed in Jun 2026. Shizune tracks 38 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
